American Oncology Network now offers BiTE therapy at over 40 partner clinics

American Oncology Network (AONC) is now offering Bispecific T-cell Engager, BiTE, therapy-also known as BiTE therapy-at more than 40 partner practice clinics in 18 states and Washington, D.C. This advancement brings cutting-edge cancer treatment directly to patients in community settings, expanding access to a class of immunotherapies that may offer new hope for those with cancers resistant to standard treatments. “Bispecific therapies are particularly important for patients whose cancers no longer respond to traditional treatments,” said Dr. Stephen “Fred” Divers, chief medical officer at AON. “By expanding access to these therapies in the community setting, AON is helping patients stay close to home while receiving some of the most advanced treatment options available.”